在湿时与年龄相关的黄斑变性中HTRA1促进物多态性
Andrew Dewan1, Mugen Liu, Stephen Hartman
1Department of Epidemiology and Public Health, Yale University, 60 College Street, New Haven, CT 06520, USA.
Science (New York, N.Y.)
|October 21, 2006
概括
在HTRA1基因的遗传变异显著增加了患湿时与年龄相关的黄斑变性 (AMD) 的风险. 这一发现确定了湿性AMD的关键遗传因素,这是视力丧失的主要原因.
科学领域:
- 遗传学 遗传学 是一个
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是50岁以上人群不可逆转的视力丧失的主要原因.
- 干性AMD与补充因子H基因的变异有关.
- 湿 AMD,新血管形式,需要识别不同的遗传风险因素.
研究的目的:
- 为了确定湿与年龄相关的黄斑变性 (AMD) 的遗传风险因素.
- 调查HTRA1基因在湿性AMD发展中的作用.
主要方法:
- 全基因组关联映射在中国人群中被采用.
- 分析了HTRA1基因的促进子区域中的单核酸多态性 (SNP).
主要成果:
- 在HTRA1基因促进体中的特定SNP被确定为湿性AMD的主要遗传风险因素.
- 该研究取得了高统计学意义 (P < 10).
- 与野生型基因型相比,具有风险基因型的个体患湿性AMD的可能性增加了10倍.
结论:
- HTRA1基因促进物多态性是湿性AMD的重要遗传决定因素.
- 这一发现提供了对湿 AMD 背后的分子机制的见解.
- 识别遗传风险因素可以有助于了解AMD的发病因子,并可能为未来的治疗策略提供信息.
更多相关视频
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Genetic Lingo
Overview